Inflammation and cancer
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 8 of the 94 sources its claims cite were checked for support.
Abstract
Recent data have expanded the concept that inflammation is a critical component of tumour progression. Many cancers arise from sites of infection, chronic irritation and inflammation. It is now becoming clear that the tumour microenvironment, which is largely orchestrated by inflammatory cells, is an indispensable participant in the neoplastic process, fostering proliferation, survival and migration. In addition, tumour cells have co-opted some of the signalling molecules of the innate immune system, such as selectins, chemokines and their receptors for invasion, migration and metastasis. These insights are fostering new anti-inflammatory therapeutic approaches to cancer development.
Overview
CoChat Summary
TL;DR
This review argues that inflammation is a critical component of tumour progression, with inflammatory cells and their mediators fostering proliferation, survival, angiogenesis, invasion and metastasis. It synthesizes evidence linking chronic infection/inflammation to cancer and discusses anti-inflammatory therapeutic opportunities.
Key findings
- Many cancers arise from sites of infection, chronic irritation and inflammation; the tumour microenvironment, largely orchestrated by inflammatory cells, is an indispensable participant in neoplasia, fostering proliferation, survival and migration.
- Upwards of 15% of malignancies worldwide are attributable to infections, a global total of 1.2 million cases per year; chronic inflammatory conditions are associated with neoplasms including colorectal carcinoma in inflammatory bowel disease and gastric cancer with chronic *Helicobacter pylori* infection, the second most common cancer globally.
- In MMTV-PyMT mammary cancer mice crossed with CSF-1-null (*Csf1op*) mice, absence of CSF-1 had no apparent early consequence, but late-stage invasive carcinoma and pulmonary metastases were significantly attenuated; targeting CSF-1 to mammary epithelium restored macrophage recruitment, primary tumour development and metastatic potential.
- Long-term aspirin/NSAID use reduces colon cancer risk by 40–50% and may be preventative for lung, oesophagus and stomach cancer; tumour cells also co-opt innate immune signalling molecules such as selectins, chemokines and their receptors for invasion, migration and metastasis.
Methods
- Narrative review; no primary experiments or new patient/animal data are reported.
- Synthesizes published literature on inflammation, innate immunity, wound healing, inflammatory cell types, chemokines, chronic inflammation-associated cancers, selectin/MMP biology and anti-inflammatory therapy.
- Main analysis is conceptual synthesis and interpretation of cited studies; no systematic search strategy, inclusion criteria or quantitative meta-analysis is described.
Limitations
- The paper states that the acquired immune response to cancer is intimately related to the inflammatory response but is beyond the scope of the article.
- Evident from the text: as a narrative review, it lacks a systematic search or formal evidence appraisal, and conclusions depend on the cited studies.
- Evident from the text: many molecular and cellular mechanisms mediating the inflammation–cancer relationship remain unresolved, and therapeutic implications are largely based on observational, animal or preclinical evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
5 Valid · 1 Not valid · 66 Not checked · 35 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition to altering the local balance of pro-angiogenic factors during melanoma development, during human cervical carcinogenesis, TAMs express VEGF-C and VEGF-D as well as the VEGF receptor-3 (VEGFR-3), all of which are implicated in formation of lymphatic vessels and lymphatic metastases17.”
What the sources say
- Supportedcites [17] Schoppmann, S. et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161, 947–956 (2002). source
The Abstract (p.1) states that in human cervical cancers the VEGF-C- and VEGF-D-producing stromal cells were identified in situ as a subset of activated TAMs (CD68, CD23, CD14) that 'also expressed the VEGF-C-and VEGF-D-specific tyrosine kinase receptor VEGFR-3'. The Discussion reinforces this: 'All VEGF-C-and VEGF-D-producing TAMs co-expressed also the corresponding tyrosine kinase receptor VEGFR-3', and links their density to peritumoral lymphatic microvessel density, lymphangiosis carcinomatosa and lymph-node metastasis, i.e. lymphatic vessel formation and lymphatic spread. The melanoma clause of the citing sentence belongs to a different citation and was not judged here. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Tumour cells produce various cytokines and chemokines that attract leukocytes.”
What the sources say
- Could not verifycites [11] Kuper, H., Adami, H. O. & Trichopoulos, D. Infections as a major preventable cause of human cancer. J. Intern. Med. 248, 171–183 (2000). sourceExperimental — accuracy not yet measured
The Helicobacter pylori section (p. 9) describes white blood cells being attracted during inflammation, followed by increased cytokine production. The Mechanisms section (p. 2) discusses inflammation caused by infection. Neither passage says that tumour cells produce cytokines or chemokines to attract leukocytes; searches for those terms found no supporting passage. (LLM, conf=0.76)
- Partly supportedcites [12] Wahl, L. M. & Kleinman, H. K. Tumor-associated macrophages as targets for cancer therapy. J. Natl Cancer Inst. 90, 1583–1584 (1998). sourceExperimental — accuracy not yet measured
On p. 1, the paper says tumor-derived attractants, including monocyte chemotactic protein-1, recruit tumor-associated macrophages to tumors. It also lists several tumor-derived cytokines, but describes them as reducing macrophage cytotoxicity, not attracting leukocytes. The claim extends the recruitment point beyond the macrophages and attractant discussed in the paper. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The key difference between PyMT mice and PyMT/Csf1op/Csf1op mice is not in the apparent proliferative capacity of neoplastic epithelial cells, but in the failure to recruit mature macrophages into neoplastic tissue in the absence of CSF-1.”
What the sources say
- Supportedcites [21] Lin, E. Y., Nguyen, A. V., Russell, R. G. & Pollard, J. W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193, 727–740 (2001). source
The Introduction reports that CSF-1 deficiency did not affect primary mammary tumor growth but delayed macrophage recruitment. The Results section (“Absence of CSF-1 Does Not Effect Growth of the Primary Mammary Tumor”) found no significant difference in tumor-cell proliferation, and the Discussion reports no macrophage infiltration at the tumor site in CSF-1-null PyMT mice. Page numbers are not provided in our copy. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Genetic and functional experiments indicate that neutrophils, mast cells, eosinophils and activated T lymphocytes also contribute to malignancies by releasing extracellular proteases, pro-angiogenic factors and chemokines11,23–26.”
What the sources say
- Partly supportedcites [11] Kuper, H., Adami, H. O. & Trichopoulos, D. Infections as a major preventable cause of human cancer. J. Intern. Med. 248, 171–183 (2000). sourceExperimental — accuracy not yet measured
The Mechanisms section (p. 2) says inflammatory phagocytes produce reactive oxygen and nitrogen species that can favor carcinogenesis. The H. pylori section (p. 9) links recruited white blood cells and cytokines to oxidative DNA damage. Neither passage establishes the claimed contribution of all four named cell types through extracellular proteases, pro-angiogenic factors, and chemokines, or cites genetic and functional experiments for it. (LLM, conf=0.78)
- Not checked yetcites [23] DiCarlo, E. et al. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 97, 339–345 (2001). source
- Partly supportedcites [24] Coussens, L. M. et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13, 1382–1397 (1999). sourceExperimental — accuracy not yet measured
The Conclusion (page unavailable) links mast cells to angiogenesis during premalignant squamous carcinogenesis through the release of pro-angiogenic proteases. The paper does not establish the claimed roles of neutrophils, eosinophils or activated T lymphocytes, or their release of chemokines. (LLM, conf=0.86)
- Not checked yetcites [25] Coussens, L. M., Tinkle, C. L., Hanahan, D. & Werb, Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490 (2000). source
- Partly supportedcites [26] Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) identifies mast cells and neutrophils as suppliers of MMP-9 in a model of squamous carcinogenesis, and reports that MMP-9 can mobilize VEGF during angiogenesis. Our copy does not establish the claimed roles for eosinophils or activated T lymphocytes, or say that these cells contribute by releasing chemokines. (LLM, conf=0.87)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
In the paper
“Indeed, macrophage infiltration is closely associated with the depth of invasion of primary melanoma due, in part, to macrophage-regulated tumour-associated angiogenesis19.”
What the sources say
- Not checked yetcites [19] Ono, M., Torisu, H., Fukushi, J., Nishie, A. & Kuwano, M. Biological implications of macrophage infiltration in human tumor angiogenesis. Cancer Chemother. Pharmacol. 43, S69–S71 (1999). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
76 more claims
Create a free account to see all 107 claims and to verify the 86 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 22
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Chronic inflammation is also important for carcinogenesis, as pro-inflammatory cytokines, including IL-1β, can be tumour promoting6,111.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many of these processes also occur in cancer as most of them are inflammation-related, including hypoxia-induced neovascularization, endothelial dysfunction, permeability of the microvasculature and the upregulation of adhesion molecules to facilitate the recruitment of cells30,31.”
From Perspectives and opportunities for nanomedicine in the management of atherosclerosis (2011) · cites this paper as [30]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inflammatory cells such as macrophages and neutrophils can cause immunosuppression in the TME.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Besides promoting cell proliferation, the action of cytokines in promoting cancer development includes antagonizing anti-tumor immune response, recruiting tumor-supportive stromal cells and immune-suppressive cells, inducing angiogenesis and metastasis, and altering the responses to therapeutic agents (10, 15)”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, rather than the dogma that oncogenesis is intrinsically triggered in pre-neoplastic cells, environmental factors, such as infection, stress, obesity, aging and smoking, each of which can induce chronic inflammation, could be a major cause of oncogenesis (4, 6, 9, 233).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [4]
Experimental — accuracy not yet measured
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
A DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Self-citationMatrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
Coussens, L. M., Fingleton, B., & Matrisian, L. M. (2002) · Science · doi:10.1126/science.1067100 · Cited by 2,761
Self-citationThe Biology of Chemokines and their Receptors
Rossi, D., & Zlotnik, A. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.217 · Cited by 2,410 · cited 1×
“A family of chemotactic cytokines, named chemokines, which possess a relatively high degree of specificity for chemoattraction of specific leukocyte population”
Inflammation. Basic principles and clinical correlates
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90156-x · Cited by 2,393
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
The role of cyclooxygenases in inflammation, cancer, and development
Williams, C. S., Mann, M., & DuBois, R. N. (1999) · Oncogene · doi:10.1038/sj.onc.1203286 · Cited by 1,417
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Overall, C. M., & López-Otín, C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc884 · Cited by 1,349
MMP-9 Supplied by Bone Marrow–Derived Cells Contributes to Skin Carcinogenesis
Coussens, L. M., Tinkle, C. L., Hanahan, D., & Werb, Z. (2000) · Cell · doi:10.1016/s0092-8674(00)00139-2 · Cited by 1,306
Self-citationThe Functional Role of the ELR Motif in CXC Chemokine-mediated Angiogenesis
Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriott, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.27348 · Cited by 1,222
The role of STATs in transcriptional control and their impact on cellular function
Bromberg, J., & Darnell, J. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203476 · Cited by 1,201
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., & Hanahan, D. (1999) · Genes & Development · doi:10.1101/gad.13.11.1382 · Cited by 946 · cited 1×
“Genetic and functional experiments indicate that neutrophils, mast cells, eosinophils and activated T lymphocytes also contribute to malignancies by releasing extracellular proteases, pro-angiogenic factors and chemokine”
Self-citationIntravital imaging of cell movement in tumours
Condeelis, J., & Segall, J. E. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1231 · Cited by 929
Schoppmann, S. F., Birner, P., Stöckl, J., Kalt, R., Ullrich, R., Caucig, C., Kriehuber, E., Nagy, K., Alitalo, K., & Kerjaschki, D. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64255-1 · Cited by 794
Infections as a major preventable cause of human cancer
Kuper, H., Adami, H. ‐., & Trichopoulos, D. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00742.x · Cited by 740
Borsig, L., Wong, R., Feramisco, J., Nadeau, D. R., Varki, N. M., & Varki, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061615598 · Cited by 714 · cited 1×
“P-selectin facilitates human carcinoma metastasis in immunodeficient mice by mediating early interactions of platelets with blood-borne tumour cells via their cell-surface mucins, a process that can be blocked by hepari”
Chronic inflammation and cancer.
Shacter, E. B., & Weitzman, S. A. (2002) · PubMed · Cited by 694
A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., & Beach, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1375 · Cited by 649 · cited 1×
“MIF is a potent cytokine that overcomes p53 function by suppressing its transcriptional activit”
Inflammation: Basic Principles and Clinical Correlates
Ehrlich, G. E. (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.283.1.123 · Cited by 622
Chronic Inflammation and Cancer
Oshima, M. (2013) · 肥満研究 · Cited by 580
Impaired wound healing in mice with a disrupted plasminogen gene
Rømer, J., Bugge, T. H., Fyke, C., Lund, L. R., Flick, M. J., Degen, J. L., & Danø, K. (1996) · Nature Medicine · doi:10.1038/nm0396-287 · Cited by 561
Ernst, P. B., & Gold, B. D. (2000) · Annual Review of Microbiology · doi:10.1146/annurev.micro.54.1.615 · Cited by 554
Mechanisms of TGF-β signaling in regulation of cell growth and differentiation
Moustakas, A., Pardali, K., Gaal, A., & Heldin, C.-H. (2002) · Immunology Letters · doi:10.1016/s0165-2478(02)00023-8 · Cited by 541
Tumor necrosis factor or tumor promoting factor?
Balkwill, F. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00020-x · Cited by 520
Hübner, G., Brauchle, M., Smola, H., Madlener, M., Fässler, R., & Werner, S. (1996) · Cytokine · doi:10.1006/cyto.1996.0074 · Cited by 500
Nitric oxide and oxygen radicals in infection, inflammation, and cancer.
Maeda, H., & Akaike, T. (1998) · PubMed · Cited by 497
Tebbutt, N. C., Giraud, A. S., Inglese, M., Jenkins, B., Waring, P., Clay, F. J., Malki, S., Alderman, B. M., Grail, D., Hollande, F., et al. (2002) · Nature Medicine · doi:10.1038/nm763 · Cited by 474
P-selectin deficiency attenuates tumor growth and metastasis
Kim, Y. J., Borsig, L., Varki, N. M., & Varki, A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.16.9325 · Cited by 454
Landers, C. J., Cohavy, O., Misra, R., Yang, H., Lin, Y., Braun, J., & Targan, S. R. (2002) · Gastroenterology · doi:10.1053/gast.2002.35379 · Cited by 440
The intriguing role of polymorphonuclear neutrophils in antitumor reactions
Di Carlo, E., Forni, G., Lollini, P., Colombo, M. P., Modesti, A., & Musiani, P. (2001) · Blood · doi:10.1182/blood.v97.2.339 · Cited by 419
Borsig, L., Wong, R., Hynes, R. O., Varki, N. M., & Varki, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261704098 · Cited by 400
Blaser, M. J., Chyou, P.-H., & Nomura, A. M. Y. (1995) · PubMed · Cited by 399
Chemokines: agents for the immunotherapy of cancer?
Homey, B., Müller, A., & Zlotnik, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri748 · Cited by 398 · cited 1×
“A family of chemotactic cytokines, named chemokines, which possess a relatively high degree of specificity for chemoattraction of specific leukocyte population”
Jensen, U. B., Lowell, S., & Watt, F. M. (1999) · Development · doi:10.1242/dev.126.11.2409 · Cited by 373
Wound healing: the role of the macrophage and other immune cells.
DiPietro, L. A. (1995) · PubMed · Cited by 366
Elder, D. J. E., Halton, D. E., Hague, A., & Paraskeva, C. (1997) · PubMed · Cited by 366
Torisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., NAKAYAMA, J., Nishioka, Y., Sone, S., & Kuwano, M. (2000) · PubMed · Cited by 363
Spinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
García Rodríguez, L. A., & Huerta-Alvarez, C. (2001) · Epidemiology · doi:10.1097/00001648-200101000-00015 · Cited by 359
Vicari, A. P., & Caux, C. (2002) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(01)00033-8 · Cited by 351 · cited 1×
“Other CXCR2 ligands have been identified as having autocrine roles in the growth of pancreatic, head and neck, and non-small-cell lung carcinom”
Inflammation and the development of pancreatic cancer
Farrow, B., & Evers, B. M. (2002) · Surgical Oncology · doi:10.1016/s0960-7404(02)00015-4 · Cited by 338
Grützkau, A., Krüger-Krasagakes, S., Baumeister, H., Schwarz, C., Kögel, H., Welker, P., Lippert, U., Henz, B. M., & Möller, A. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.4.875 · Cited by 337
CONDITIONAL NEOPLASMS AND SUBTHRESHOLD NEOPLASTIC STATES
Rous, P., & Kidd, J. G. (1941) · Journal of Experimental Medicine · doi:10.1084/jem.73.3.365 · Cited by 329
Nonsteroidal Anti-Inflammatory Drugs and Cancer Prevention
Baron, J. A., & Sandler, R. S. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.511 · Cited by 297
Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells.
Jonjić, N., Peri, G., Bernasconi, S., Sciacca, F. L., Colotta, F., Pelicci, P., Lanfrancone, L., & Mantovani, A. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.4.1165 · Cited by 290
WOUND HEALING: THE ROLE OF THE MACROPHAGE AND OTHER IMMUNE CELLS
DiPietro, L. A. (1995) · Shock · doi:10.1097/00024382-199510000-00001 · Cited by 285
Arenberg, D. A., Keane, M. P., DiGiovine, B., Kunkel, S. L., Morris, S. B., Xue, Y. Y., Burdick, M. D., Glass, M. C., Iannettoni, M. D., & Strieter, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3145 · Cited by 259
Torisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., Nakayama, J., Nishioka, Y., Sone, S., & Kuwano, M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000115)85:2%3c182::aid-ijc6%3e3.0.co;2-m · Cited by 254
Activation of STAT3 by the Hepatitis C Virus Core Protein Leads to Cellular Transformation
Yoshida, T., Hanada, T., Tokuhisa, T., Kosai, K.-I., Sata, M., Kohara, M., & Yoshimura, A. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20012127 · Cited by 236
Tumors and inflammatory infiltrates: Friends or foes?
Brigati, C., Noonan, D. M., Albini, A., & Benelli, R. (2002) · Clinical & Experimental Metastasis · doi:10.1023/a:1015587423262 · Cited by 230 · cited 1×
“TAMs have a dual role in neoplasms — although they may kill neoplastic cells following activation by IL-2, interferon and IL-12 (ref”
Scholl, S. M., Pallud, C., Beuvon, F., Hacene, K., Stanley, E. R., Rohrschneider, L., Tang, R., Pouillart, P., & Lidereau, R. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.2.120 · Cited by 226
Regulation of keratinocyte growth factor gene expression by interleukin 1.
Chedid, M., Rubin, J. S., Csaky, K. G., & Aaronson, S. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34123-6 · Cited by 218
Regional analysis of p53 mutations in rheumatoid arthritis synovium
Yamanishi, Y., Boyle, D. L., Rosengren, S., Green, D. R., Zvaifler, N. J., & Firestein, G. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.152333199 · Cited by 214
Allavena, P., Sica, A., Vecchi, A., Locati, M., Sozzani, S., & Mantovani, A. (2000) · Immunological Reviews · doi:10.1034/j.1600-065x.2000.17714.x · Cited by 172
Chronic immune activation and inflammation in the pathogenesis of aids and cancer
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)84008-8 · Cited by 166
Biological implications of macrophage infiltration in human tumor angiogenesis
Ono, M., Torisu, H., Fukushi, J.-I., Nishie, A., & Kuwano, M. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051101 · Cited by 157
Kondo, H., Ichikawa, Y., & Imokawa, G. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199803)28:03<799::aid-immu799>3.0.co;2-5 · Cited by 152
THE EXPERIMENTAL DISCLOSURE OF LATENT NEOPLASTIC CHANGES IN TARRED SKIN
MacKenzie, I., & Rous, P. (1941) · The Journal of Experimental Medicine · doi:10.1084/jem.73.3.391 · Cited by 148
Kleeff, J., Kusama, T., Rossi, D. L., Ishiwata, T., Maruyama, H., Friess, H., Büchler, M. W., Zlotnik, A., & Korc, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990517)81:4<650::aid-ijc23>3.0.co;2-# · Cited by 148
Expression and growth-promoting function of the IL-8 receptor β in human melanoma cells
Norgauer, J., Metzner, B., & Schraufstätter, I. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.3.1132 · Cited by 144
The role of chemoattraction in cancer metastases
Moore, M. A. S. (2001) · BioEssays · doi:10.1002/bies.1095 · Cited by 138
Owen, J. D., Strieter, R., Burdick, M., Haghnegahdar, H., Nanney, L., Shattuck-Brandt, R., & Richmond, A. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<94::aid-ijc15>3.0.co;2-5 · Cited by 133
Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.
Tsung, K., Dolan, J. P., Tsung, Y. L., & Norton, J. A. (2002) · PubMed · Cited by 129
Purification of melanoma growth stimulatory activity
Richmond, A., & Thomas, H. G. (1986) · Journal of Cellular Physiology · doi:10.1002/jcp.1041290316 · Cited by 128
Nowicki, A., Szenajch, J., Ostrowska, G., Wojtowicz, A., Wojtowicz, K., Kruszewski, A. A., Maruszynski, M., Aukerman, S. L., & Wiktor-Jedrzejczak, W. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960103)65:1<112::aid-ijc19>3.0.co;2-i · Cited by 126
Generation or large numbers of immature and mature dendritic cells from rat bone marrow cultures
Talmor, M., Mirza, A., Turley, S., Mellman, I., Hoffman, L. A., & Steinman, R. M. (1998) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(199803)28:03<811::aid-immu811>3.0.co;2-s · Cited by 121
Martins‐Green, M. M., Boudreau, N. J., & Bissell, M. J. (1994) · PubMed · Cited by 120
Tumor-Associated Macrophages as Targets for Cancer Therapy
Wahl, L. M., & Kleinman, H. K. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1583 · Cited by 110 · cited 1×
“The inflammatory component of a developing neoplasm may include a diverse leukocyte population — for example, neutrophils, dendritic cells, macrophages, eosinophils and mast cells, as well as lymphocytes — all of which are capable of producing an assorted array of cytokines, cytotoxic mediators including reactive oxyg…”
Effects of MGSA/GRO alpha on melanocyte transformation.
Balentien, E., Mufson, B. E., Shattuck, R. L., Derynck, R., & Richmond, A. J. (1991) · PubMed · Cited by 102
Neutrophils Express Tumor Necrosis Factor-α During Mouse Skin Wound Healing
Feiken, E., Rømer, J., Eriksen, J., & Lund, L. R. (1995) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12313429 · Cited by 88
Tumor Necrosis Factor-α Blockade: A Novel Therapy for Rheumatic Disease
Shanahan, J. C., & Clair, E. W. S. (2002) · Clinical Immunology · doi:10.1006/clim.2002.5191 · Cited by 86
Immunomodulatory effects of tumor-associated fibroblasts in colorectal-tumor development
Lieubeau, B., Heymann, M., Henry, F., Barbieux, I., Méflah, K., & Gr�goire, M. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990517)81:4<616::aid-ijc18>3.0.co;2-s · Cited by 85
Cytokines modulate fibroblast phenotype and epithelial-stroma interactions in rat intestine
Fritsch, C. M., Simon-Assmann, P. M., Kédinger, M., & EVANS, G. S. (1997) · Gastroenterology · doi:10.1053/gast.1997.v112.pm9041244 · Cited by 81
L-selectin can facilitate metastasis to lymph nodes in a transgenic mouse model of carcinogenesis
Qian, F., Hanahan, D., & Weissman, I. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061633698 · Cited by 80
Microorganisms and Cancer: Quest for a Therapy
Chakrabarty, A. M. (2003) · Journal of Bacteriology · doi:10.1128/jb.185.9.2683-2686.2003 · Cited by 78
Heterogeneous Stem Cells in Skin Homeostatis and Wound Repair
Meilana, A., Dewi, N. M., & Wijaya, A. (2015) · The Indonesian Biomedical Journal · doi:10.18585/inabj.v7i2.74 · Cited by 77
Chensue, S. W., Ruth, J. H., Warmington, K. S., Lincoln, P., & Kunkel, S. L. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.7.3546 · Cited by 76
Macrophage Control of Inflammation: Negative Pathways of Regulation of Inflammatory Cytokines
Mantovani, A., Muzio, M., Garlanda, C., Sozzani, S., & Allavena, P. (2000) · Novartis Foundation Symposia · doi:10.1002/0470868678.ch8 · Cited by 54
Overview of carcinogenesis: past, present and future
Yuspa, S. H. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.341 · Cited by 51
Zhang, J., Nakayama, J., Οhyama, C., Suzuki, M., Suzuki, A., Fukuda, M., & Fukuda, M. N. (2002) · PubMed · Cited by 49
Immune recognition and tumor protection
Dranoff, G. (2002) · Current Opinion in Immunology · doi:10.1016/s0952-7915(02)00315-1 · Cited by 21
Retinal Pigment Epithelium Cells Promote the Maturation of Monocytes to Macrophages in vitro
Osuský, R., Malik, P., & Ryan, S. J. (2009) · Ophthalmic Research · doi:10.1159/000267988 · Cited by 13
Antimetastatic effect of flurbiprofen and other platelet aggregation inhibitors.
Mamytbeková, A., Řežábek, K., Kacerovská, H., Grimová, J., & Svobodová, J. (1986) · PubMed · Cited by 11
Cited by
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
The NOX Family of ROS-Generating NADPH Oxidases: Physiology and Pathophysiology
Bedard, K., & Krause, K.-H. (2007) · Physiological Reviews · doi:10.1152/physrev.00044.2005 · Cited by 6,989
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Nitric Oxide and Peroxynitrite in Health and Disease
Pacher, P., Beckman, J. S., & Liaudet, L. (2007) · Physiological Reviews · doi:10.1152/physrev.00029.2006 · Cited by 6,390
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Metadata
- Authors
- Coussens, L. M., & Werb, Z.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Nature
- Published
- 2002-12
- Volume
- 420
- Issue
- 6917
- Pages
- 860-867
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC2803035
- OpenAlex
- W1965037168
- Cited by
- 15,111
- References
- 88
- Citations by year
- 2026: 328 · 2025: 590 · 2024: 701 · 2023: 849 · 2022: 873 · 2021: 934 · 2020: 858 · 2019: 827 · 2018: 742 · 2017: 775 · 2016: 756 · 2015: 773 · 2014: 776 · 2013: 749 · 2012: 689
- FWCI
- 15.43
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- V Foundation for Cancer Research
- Edward Mallinckrodt, Jr. Foundation
- Fondation pour la Recherche Médicale
- National Institutes of Health
- National Cancer Institute (P01CA072006, R01CA057621)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- inflammation, cancer, tumor microenvironment, tumor progression, chronic inflammation, infection-associated cancer, inflammatory cells, tumor cell proliferation, cell migration, metastasis, innate immune signaling, selectins, chemokines, chemokine receptors
- MeSH terms
- Animals, Chronic Disease, Humans, Inflammation, Leukocytes, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Disease Progression, Chemokines
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.